Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.

Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Cristina Morelli M, Ravaioli M, Daniele Pinna A.

Liver Transpl. 2011 Nov;17(11):1344-54. doi: 10.1002/lt.22397.

2.

Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.

Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W.

Liver Transpl. 2003 Jun;9(6):557-63.

3.

Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma.

Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, Vogel W.

Liver Transpl. 2007 Feb;13(2):272-9.

4.

Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY.

Liver Transpl. 2013 Dec;19(12):1343-53. doi: 10.1002/lt.23753.

5.

Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.

Kim JM, Kwon CH, Joh JW, Choi MS, Lee JH, Koh KC, Paik SW, Kim GS, Kim SJ, Lee SK, Yoo BC.

Transplant Proc. 2012 Mar;44(2):403-8. doi: 10.1016/j.transproceed.2012.01.067.

PMID:
22410028
6.

Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.

Hanouneh IA, Macaron C, Lopez R, Aucejo F, Zein NN.

Transplant Proc. 2011 Dec;43(10):3813-8. doi: 10.1016/j.transproceed.2011.09.043.

PMID:
22172852
7.

Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation.

Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC.

Ann Surg Oncol. 2011 Sep;18(9):2638-46. doi: 10.1245/s10434-011-1779-z. Epub 2011 May 17.

PMID:
21584831
8.

Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW.

World J Gastroenterol. 2013 Nov 21;19(43):7515-30. doi: 10.3748/wjg.v19.i43.7515. Review.

9.

An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.

Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA.

Liver Transpl. 2009 Aug;15(8):859-68. doi: 10.1002/lt.21778.

10.

Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.

Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G.

Liver Transpl. 2004 Mar;10(3):449-55.

11.

Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.

Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T.

Liver Transpl. 2012 Apr;18(4):423-33. doi: 10.1002/lt.23385.

12.

Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.

Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP.

Liver Transpl. 2002 Oct;8(10):873-83.

13.

Liver transplantation in patients with hepatocellular carcinoma across Milan criteria.

Herrero JI, Sangro B, Pardo F, Quiroga J, IƱarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J.

Liver Transpl. 2008 Mar;14(3):272-8. doi: 10.1002/lt.21368.

14.

Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.

Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA.

Clin Transplant. 2012 Jul-Aug;26(4):E359-64. doi: 10.1111/j.1399-0012.2012.01668.x. Epub 2012 Jun 13.

PMID:
22693962
15.

Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.

Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW.

Hepatology. 2005 May;41(5):1130-7.

PMID:
15841454
16.

Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.

Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY, Huo SC, Lee PC, Lee SD.

Clin Transplant. 2008 Jul-Aug;22(4):469-75. doi: 10.1111/j.1399-0012.2008.00811.x. Epub 2008 Mar 3.

PMID:
18318736
17.

Liver transplantation for hepatocellular carcinoma: indications, bridge therapy and adjuvant therapy.

Li SF, Hawxby AM, Kanagala R, Wright H, Sebastian A.

J Okla State Med Assoc. 2012 Jan;105(1):12-6. Review.

PMID:
22458042
18.

Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.

Fisher RA, Maluf D, Cotterell AH, Stravitz T, Wolfe L, Luketic V, Sterling R, Shiffman M, Posner M.

Clin Transplant. 2004 Oct;18(5):502-12.

PMID:
15344951
19.

Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma.

Sandroussi C, Dawson LA, Lee M, Guindi M, Fischer S, Ghanekar A, Cattral MS, McGilvray ID, Levy GA, Renner E, Greig PD, Grant DR.

Transpl Int. 2010 Mar 1;23(3):299-306. doi: 10.1111/j.1432-2277.2009.00980.x. Epub 2009 Oct 15.

20.

Liver transplantation for hepatocellular carcinoma: the MELD impact.

Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH.

Liver Transpl. 2004 Jan;10(1):36-41.

Supplemental Content

Support Center